For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
11
views
47
references
 Top references
cited by
40
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      504
      similar
       All similar

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Disorders of Lipid Metabolism in Chronic Kidney Disease

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cardiovascular disease (CVD) is the leading cause of death in chronic kidney disease (CKD). One of the most important pathophysiological mechanisms for CVD in patients with CKD is the widespread and possibly accelerated formation of atherosclerotic plaques due to hyperlipidemia, uremic toxins, inflammation, oxidative stress, and endothelial dysfunction. Recent studies showed that the level of oxidized low-density lipoprotein cholesterol increases, and that high-­density lipoprotein cholesterol dysfunction occurs as kidney function declines and inflammation becomes more prevalent. In this review, we aimed to discuss the effect of kidney dysfunction, oxidative stress, and inflammation on lipid ­profile.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

          Marc Bonaca, Patrice Nault, Robert Giugliano … (2018)
          The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events.
          Article 0 comments Cited 173 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The systemic nature of CKD

            Carmine Zoccali, Raymond Vanholder, Ziad Massy … (2017)
            Chronic kidney disease (CKD) affects numerous organs and systems, which in turn have effects on kidney function. This Review provides an overview of CKD as a systemic disease and discusses the multidirectional links between the kidney, bone, nervous and immune systems, and metabolism.
            Article 0 comments Cited 143 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Adhesion mechanisms regulating the migration of monocytes.

              Beat Imhof, Michel Aurrand-Lions (2004)
              Article 0 comments Cited 118 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (publisher-id): BPU
                Journal ID (nlm-ta): Blood Purif
                Journal ID (doi): 10.1159/issn.0253-5068
                Title: Blood Purification
                Publisher: S. Karger AG
                ISSN (Print): 0253-5068
                ISSN (Electronic): 1421-9735
                Publication date Subscription-year: 2018
                Publication date (Print): May 2018
                Publication date (Electronic): 27 April 2018
                Volume: 46
                Issue: 2
                Pages: 144-152
                Affiliations
                [_a] aSchool of Medicine, Koç University, Istanbul, Turkey
                [_b] bDepartment of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey
                [_c] cDepartment of Medicine, Division of Nephrology, Suleyman Demirel University School of Medicine, Isparta, Turkey
                [_d] dDepartment of Biochemistry, Koc University School of Medicine, Istanbul, Turkey
                [_e] eDivision of Renal Diseases and Hypertension, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA
                [_f] fNephrology Clinic, Dialysis and Renal Transplant Center, “C.I. PARHON” University Hospital, and “Grigore T. Popa” University of Medicine, Iasi, Romania
                Author notes
                *Mehmet Kanbay, MD, Koç University School of Medicine, Rumelifeneri Yolu, Sariyer, TR–34450 Istanbul (Turkey), E-Mail mkanbay@ku.edu.tr, drkanbay@yahoo.com
                Article
                Publisher ID: 488816 Other ID: Blood Purif 2018;46:144–152
                DOI: 10.1159/000488816
                PubMed ID: 29705798
                SO-VID: 4871efac-58c9-46e8-b4e1-273b860f0708
                Copyright © © 2018 S. Karger AG, Basel
                License:

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Date received : 18 December 2017
                Date accepted : 25 March 2018
                Page count
                Figures: 1, Tables: 1, Pages: 9
                Categories
                Subject: In-Depth Review

                ScienceOpen disciplines: Cardiovascular Medicine,Nephrology
                Keywords: Hyperlipidemia,Chronic kidney disease,Oxidized low-density lipoprotein
                Data availability:
                ScienceOpen disciplines: Cardiovascular Medicine, Nephrology
                Keywords: Hyperlipidemia, Chronic kidney disease, Oxidized low-density lipoprotein

                Comments

                Comment on this article

                scite_

                Similar content504

                See all similar

                Cited by38

                See all cited by

                Most referenced authors905

                See all reference authors